|
|
Vaccine Detail
|
gp100 mature dendritic cell vaccine |
| Vaccine Information |
- Vaccine Name: gp100 mature dendritic cell vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: gp100 melanoma peptides (G209-2M and G280-9V) and 10 unique melanoma tumor-specific peptides (NCT00683670)
- Immunization Route: Intravenous injection (i.v.)
- Description: Using dendritic cells (a kind of white blood cell) as a vaccine could stimulate your own immune system to react to your melanoma cells. Autologous dendritic cells are pulsed with 2 gp100 melanoma peptides (G209-2M and G280-9V) plus up to an additional 10 unique melanoma tumor-specific peptides. Patients also receive cyclophosphamide 300mg/m2 IV in order to deplete regulatory T cells.(NCT00683670)
|
| Host Response |
|
|
| References |
NCT00683670: Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma [https://clinicaltrials.gov/study/NCT00683670]
|
|
